Cargando…

Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study

BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chuancai, He, Zhisong, Lei, Wei, Chen, Li, Shen, Dan, Wang, Xiaofei, Xu, Deyu, Xu, Ying, Huang, Jian’an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645737/
https://www.ncbi.nlm.nih.gov/pubmed/36352356
http://dx.doi.org/10.1186/s12879-022-07808-2
_version_ 1784827018477568000
author Xu, Chuancai
He, Zhisong
Lei, Wei
Chen, Li
Shen, Dan
Wang, Xiaofei
Xu, Deyu
Xu, Ying
Huang, Jian’an
author_facet Xu, Chuancai
He, Zhisong
Lei, Wei
Chen, Li
Shen, Dan
Wang, Xiaofei
Xu, Deyu
Xu, Ying
Huang, Jian’an
author_sort Xu, Chuancai
collection PubMed
description BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. RESULTS: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5–14] days) and PV (13 [IQR, 9–16.75] days) groups than in the UV group (15 [IQR, 11.75–17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08–63.59] and 0.3 S/co [IQR, 0.05–2.29], respectively) and PV (0.68 S/co [IQR, 0.14–28.69] and 0.12 S/co [0.03–5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03–0.47] and 0.04 S/co [IQR, 0.02–0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). CONCLUSIONS: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07808-2.
format Online
Article
Text
id pubmed-9645737
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96457372022-11-14 Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study Xu, Chuancai He, Zhisong Lei, Wei Chen, Li Shen, Dan Wang, Xiaofei Xu, Deyu Xu, Ying Huang, Jian’an BMC Infect Dis Research BACKGROUND: At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. METHODS: We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. RESULTS: The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5–14] days) and PV (13 [IQR, 9–16.75] days) groups than in the UV group (15 [IQR, 11.75–17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08–63.59] and 0.3 S/co [IQR, 0.05–2.29], respectively) and PV (0.68 S/co [IQR, 0.14–28.69] and 0.12 S/co [0.03–5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03–0.47] and 0.04 S/co [IQR, 0.02–0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). CONCLUSIONS: Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07808-2. BioMed Central 2022-11-09 /pmc/articles/PMC9645737/ /pubmed/36352356 http://dx.doi.org/10.1186/s12879-022-07808-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Chuancai
He, Zhisong
Lei, Wei
Chen, Li
Shen, Dan
Wang, Xiaofei
Xu, Deyu
Xu, Ying
Huang, Jian’an
Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title_full Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title_fullStr Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title_full_unstemmed Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title_short Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
title_sort comparison of the duration of viral rna shedding and anti-sars-cov-2 spike igg and igm antibody titers in covid-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645737/
https://www.ncbi.nlm.nih.gov/pubmed/36352356
http://dx.doi.org/10.1186/s12879-022-07808-2
work_keys_str_mv AT xuchuancai comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT hezhisong comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT leiwei comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT chenli comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT shendan comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT wangxiaofei comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT xudeyu comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT xuying comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy
AT huangjianan comparisonofthedurationofviralrnasheddingandantisarscov2spikeiggandigmantibodytitersincovid19patientswhowerevaccinatedwithinactivatedvaccinesornotaretrospectivestudy